All Stories

  1. Bronchodilators in bronchiectasis: there is light but it is still too dim

    Article • European Respiratory Journal, June 2022, European Respiratory Society (ERS)

    Mario Cazzola

  2. Gender differences in COPD management in a Sicilian general practice setting: a cohort study evaluating the impact of educational interventions

    Article • ERJ Open Research, July 2020, European Respiratory Society (ERS)

    Mario Cazzola

  3. α1-Antitrypsin deficiency and chronic respiratory disorders

    Article • European Respiratory Review, February 2020, European Respiratory Society (ERS)

    Mario Cazzola

  4. The future of bronchodilation: looking for new classes of bronchodilators

    Article • European Respiratory Review, December 2019, European Respiratory Society (ERS)

    Mario Cazzola

  5. Pharmacology and Therapeutics of Bronchodilators Revisited

    Article • Pharmacological Reviews, December 2019, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Mario Cazzola

  6. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation

    Article • International Journal of Chronic Obstructive Pulmonary Disease, December 2019, Taylor & Francis

    Peter Calverley, Mario Cazzola, Dr Arrigo FG CICERO, edoardo pozzi

  7. A long-term (2 years) efficacy and safety study of doxofylline in the treatment of asthma

    Article • September 2019, European Respiratory Society (ERS)

    Mario Cazzola

  8. Efficacy of erdosteine, carbocysteine, and N-acetylcysteine in COPD: a comparative analysis

    Article • September 2019, European Respiratory Society (ERS)

    Mario Cazzola

  9. A potential role of triple therapy for asthma patients

    Article • Expert Review of Respiratory Medicine, September 2019, Taylor & Francis

    Mario Cazzola

  10. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD

    Article • Expert Opinion on Investigational Drugs, September 2019, Taylor & Francis

    Mario Cazzola

  11. Pharmacological treatment and current controversies in COPD

    Article • F1000Research, August 2019, Faculty of 1000, Ltd.

    Mario Cazzola

  12. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease

    Article • Expert Opinion on Pharmacotherapy, February 2019, Taylor & Francis

    Mario Cazzola, josuel ora

  13. An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD

    Article • European Respiratory Journal, November 2018, European Respiratory Society (ERS)

    Mario Cazzola

  14. Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents

    Article • Expert Opinion on Pharmacotherapy, October 2018, Taylor & Francis

    josuel ora, Mario Cazzola

  15. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease

    Article • Expert Opinion on Drug Metabolism & Toxicology, October 2018, Taylor & Francis

    Mario Cazzola

  16. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

    Article • International Journal of Chronic Obstructive Pulmonary Disease, October 2018, Dove Medical Press

    Professor Enrico M. Clini, Professor Fulvio Braido, Mario Cazzola

  17. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis [Corrigendum]

    Article • International Journal of Chronic Obstructive Pulmonary Disease, October 2018, Dove Medical Press

    josuel ora, Mario Cazzola

  18. New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology

    Article • International Journal of Chronic Obstructive Pulmonary Disease, September 2018, Dove Medical Press

    Mario Cazzola, Dr Nicola A. Hanania

  19. How does race/ethnicity influence pharmacological response to asthma therapies?

    Article • Expert Opinion on Drug Metabolism & Toxicology, March 2018, Taylor & Francis

    Mario Cazzola, Dr Nicola A. Hanania

  20. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab

    Article • Expert Opinion on Drug Safety, March 2018, Taylor & Francis

    Mario Cazzola

  21. Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how

    Article • Expert Review of Respiratory Medicine, February 2018, Taylor & Francis

    Mario Cazzola

  22. Doxofylline is not just another theophylline!

    Article • International Journal of Chronic Obstructive Pulmonary Disease, December 2017, Dove Medical Press

    Mario Cazzola

  23. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis

    Article • International Journal of Chronic Obstructive Pulmonary Disease, December 2017, Dove Medical Press

    josuel ora, Mario Cazzola

  24. Acute exacerbations of COPD: risk factors for failure and relapse

    Article • International Journal of Chronic Obstructive Pulmonary Disease, September 2017, Dove Medical Press

    MD Ernesto Crisafulli, Mario Cazzola, Professor francesco blasi, Andrea Gramegna, eva polverino

  25. Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease

    Article • Journal of Comparative Effectiveness Research, August 2017, Future Medicine

    Mario Cazzola

  26. An update on the pharmacotherapeutic management of lower respiratory tract infections

    Article • Expert Opinion on Pharmacotherapy, May 2017, Taylor & Francis

    Mario Cazzola, Professor francesco blasi

  27. Tiotropium formulations and safety: a network meta-analysis

    Article • Therapeutic Advances in Drug Safety, January 2017, SAGE Publications

    Mario Cazzola

  28. Airflow obstruction: is it asthma or is it COPD?

    Article • International Journal of Chronic Obstructive Pulmonary Disease, November 2016, Dove Medical Press

    josuel ora, Mario Cazzola

  29. COPD: the patient perspective

    Article • International Journal of Chronic Obstructive Pulmonary Disease, February 2016, Dove Medical Press

    Mario Cazzola

  30. Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease

    Article • International Journal of Chronic Obstructive Pulmonary Disease, January 2016, Dove Medical Press

    Professor Alessandro Sanduzzi, Mario Cazzola

  31. Influence ofN-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis

    Article • European Respiratory Review, August 2015, European Respiratory Society (ERS)

    Mario Cazzola

  32. Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life

    Article • International Journal of Chronic Obstructive Pulmonary Disease, July 2015, Dove Medical Press

    Mario Cazzola

  33. A review of the most common patient-reported outcomes in COPD – revisiting current knowledge and estimating future challenges

    Article • International Journal of Chronic Obstructive Pulmonary Disease, April 2015, Dove Medical Press

    Mario Cazzola, Dr Nicola A. Hanania

  34. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease

    Article • Expert Opinion on Drug Safety, January 2015, Informa Healthcare

    Mario Cazzola

  35. The clinical use of regenerative therapy in COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, December 2014, Taylor & Francis

    Dr Roberto Lipsi, Mario Cazzola

  36. Indacaterol for the treatment of chronic obstructive pulmonary disease

    Article • Expert Opinion on Pharmacotherapy, November 2014, Informa Healthcare

    Mario Cazzola

  37. Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease

    Article • Expert Review of Clinical Pharmacology, November 2014, Taylor & Francis

    Mario Cazzola

  38. Triple combinations in chronic obstructive pulmonary disease – is three better than two?

    Article • Expert Opinion on Pharmacotherapy, October 2014, Informa Healthcare

    Mario Cazzola

  39. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol

    Article • Drug Design Development and Therapy, October 2013, Taylor & Francis

    Mario Cazzola